Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
Need more information
b Patients new to the Wegovy Savings Offer and NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg
How click conquered chemistry
- The clinical indication for use (e.g., blood-brain barrier disruption, tumor, inflammation) - The MRI or diagnostic procedure associated with the contra,st including date and provider order - The time and route of administration (e.g., IV bolus), and any patient reactions or observations
And, they grow the more consistent you are